Brazil vs Senegal: Average cost of multi drug-resistant tuberculosis treatment
Brazil
4,102 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Brazil rank
10th
Senegal rank
12th
Average cost of multi drug-resistant tuberculosis treatment over time
- Brazil
- Senegal
How they compare
Brazil currently reports 4,102 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal, a difference of 674 constant 2022 US$.
That makes Brazil's figure about 1.2 times Senegal's.
The two have swapped places 2 times across 6 shared years of data; in 2018 it was Brazil ahead.
Brazil ranks 10th and Senegal ranks 12th of 92 countries.
Across the 2 decades both report, Brazil averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Brazil | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,514 constant 2022 US$ | 2,555 constant 2022 US$ | 41.5 constant 2022 US$ | Senegal |
| 2020s | 3,332 constant 2022 US$ | 2,913 constant 2022 US$ | 419.5 constant 2022 US$ | Brazil |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Brazil or Senegal?
- Brazil, at 4,102 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Brazil and Senegal?
- 674 constant 2022 US$, with Brazil ahead.
- How many years of comparable data are there for Brazil and Senegal?
- 6 years are reported by both, from 2018 to 2024.
- How do Brazil and Senegal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Brazil ranks 10th and Senegal ranks 12th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.